Merkel Cell Carcinoma Market and Growing Geriatric Population Will Grow the Global Market at an Approximate CAGR Of 7.40% during Forecasted Period, 2017-2023

Increasing prevalence of Merkel cell carcinoma and growing geriatric population are estimated to be the major drivers for the market growth during the forecast period. Moreover, increasing R&D expenses by the key market players, rising mortality rate by MCC, and growing healthcare expenditure is further boosting the market growth. However, the high cost of therapeutics and related side effects along with the lack of awareness and low per capita healthcare expenditures in the developing economies restrains the market growth.

Segmentation

The global Merkel cell carcinoma market is segmented on the basis of diagnosis, treatment, and end users. On the basis of the diagnosis, the market is categorized into physical examination, sentinel node biopsy, imaging tests, and others. The imaging tests segment is sub-segmented into X-ray, computed tomography (CT), positron emission tomography (PET), and others. On the basis of the treatment, the market is segmented into surgery, radiation therapy, chemotherapy, and others. The chemotherapy segment is sub-segmented into etoposide, cisplatin, and others. On the basis of the end user, the market is segmented into hospitals & clinics, diagnostic centers, research organization, and others.

Get a sample report at https://www.marketresearchfuture.com/sample_request/5343 .

Regional Analysis

The Americas dominate the global Merkel cell carcinoma market. Presence of a well-developed healthcare sector and high per capita healthcare expenditures provides favorable backgrounds for market growth within the region. Additionally, the presence of the major market players within the region fuels the market growth. Followed by the Americas, Europe leads the Merkel cell carcinoma market. Availability of funds for research, huge patient population, and government support for research & development is estimated to drive the market growth within the region. Asia Pacific is the fastest growing region for the market due to the presence of economies like India, Australia, and China and developing healthcare sector in the market. Increasing prevalence of skin cancer, growing geriatric population, and rising healthcare expenditure boost the market growth within the region. On the other hand, the Middle East & Africa has the least share in the Merkel cell carcinoma market due to the presence of poor economies and stringent government policies, especially in the African region. Majority of the market of this region is held by the Middle East.

Key Players

Pfizer Inc. (U.S.), Merck & Co., Inc. (U.S.), OncoSec Medical Incorporated (U.S.), Bristol-Myers Squibb Company (U.S.), General Electric Company (U.S.), Siemens Medical Solutions USA, Inc. (Germany), CANON MEDICAL SYSTEMS CORPORATION (Japan), Philips Health Care (The Netherlands), AstraZeneca (U.K), Mediso Ltd. Endomagnetics Limited (Hungary), and others are some of the major players in the global Merkel cell carcinoma market.

Browse Complete Report at https://www.marketresearchfuture.com/reports/merkel-cell-carcinoma-market-5343 .

Merkel cell carcinoma is a rare and aggressive type of skin cancer with a high risk of recurrence and metastasis. Most recurrences occur within two years after the diagnosis of the primary tumor. The main cause of the disease is Merkel cell polyomavirus (MCV). Majority of the geriatric population is affected by the disease. Moreover, the risk of developing the disease increases with long exposure to the sun. Thus, factors like increasing prevalence of Merkel cell carcinoma and growing geriatric population are estimated to be the major drivers for the market growth during the forecast period. According to a study published in the Current Dermatology Reports journal in 2014, the annual incidence of MCC was 0.6 per 100,000 people. Moreover, according to the United Nations Population Fund, the total geriatric population is expected to increase from 12.3% of the global population in 2016 to 22.0% of the global population by 2050. Moreover, increasing expenditure in R&D by the key market players, rising mortality rate by MCC, and growing healthcare expenditure are some of the factors that boost the market growth during the forecast period. However, the high cost of therapeutics and related side effects, lack of awareness, and low per capita healthcare expenditures in the middle and low-income countries is estimated to restrain the market growth during the forecast period.

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us
Market Research Future
Maharashtra, India
+1 646 845 9312
Email: sales@Marketresearchfuture.Com

This release was published on openPR.